CARMAT | Sales 2023 | 2.8M 3.04M 4.15M | Sales 2024 * | 14.85M 16.14M 22.02M | Capitalization | 104M 113M 155M |
|---|---|---|---|---|---|
| Net income 2023 | -53M -57.62M -78.59M | Net income 2024 * | -38M -41.31M -56.35M | EV / Sales 2023 | 59.2 x |
| Net Debt 2023 * | 49.63M 53.96M 73.6M | Net Debt 2024 * | 61.25M 66.59M 90.82M | EV / Sales 2024 * | 11.2 x |
| P/E ratio 2023 |
-3.09
x | P/E ratio 2024 * |
-2.22
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 93.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Carmat
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | - | 16-08-31 |
Alain Carpentier
FOU | Founder | 91 | 08-06-24 |
| Director of Finance/CFO | - | 18-12-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
| Director/Board Member | 85 | 16-04-11 | |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
2024-05-29
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +12.84% | 128B | |
| -8.80% | 10.9B | |
| -0.49% | 8.69B | |
| +35.87% | 5.48B | |
| -23.18% | 4.72B | |
| -10.78% | 2.76B | |
| -14.85% | 2.05B | |
| -13.29% | 1.93B | |
| -27.86% | 1.67B |
